Aandeel EBAC EURO BIOT
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen EURO BIOT

Aandelen

EBAC

KYG3167F1028

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 10-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
12,07 USD +0,88% Intraday-grafiek van EURO BIOT -5,70% +7,86%
2023 Oculis SA heeft de overname afgerond van European Biotech Acquisition Corp. (NasdaqCM:EBAC) van Lsp Sponsor Ebac B.V. en anderen in een omgekeerde fusie. CI
2023 European Biotech Acquisition Corp. Rapporteert resultaten voor het volledige jaar eindigend op 31 december 2022 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index
Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.
EUROPEAN BIOTECH ACQUISITION CORP. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
European Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
EUROPEAN BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt
EUROPEAN BIOTECH ACQUISITION CORP. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
EUROPEAN BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
EUROPEAN BIOTECH ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
EUROPEAN BIOTECH ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
European Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
European Biotech Acquisition, Oculis Strike Merger Agreement
European Biotech Acquisition : Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology - Form 8-K
EUROPEAN BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million.
EUROPEAN BIOTECH ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
EUROPEAN BIOTECH ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
European Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022
EUROPEAN BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers EBAC
  4. Nieuws EURO BIOT
  5. Andere talen